Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-22T08:53:29.070Z Has data issue: false hasContentIssue false

Serum Concentration of Depot Neuroleptics in Tardive Dyskinesia

Published online by Cambridge University Press:  29 January 2018

A. F. Fairbairn
Affiliation:
Department of Psychiatry, University of Newcastle upon Tyne, NE1 4LP
F. J. Rowell
Affiliation:
Department of Pharmaceutical Chemistry, Sunderland Polytechnic, Sunderland
S. M. Hui
Affiliation:
Department of Pharmaceutical Chemistry, Sunderland Polytechnic, Sunderland
F. Hassanyeh
Affiliation:
University of Newcastle upon Tyne
A. J. Robinson
Affiliation:
University of Newcastle upon Tyne
D. Eccleston
Affiliation:
University of Newcastle upon Tyne

Summary

Using radioimmunoassay techniques, serum levels of depot neuroleptics, fluphenazine and flupenthixol, were estimated in two groups of chronic schizophrenic patients with, and without, tardive dyskinesia. There were high correlations between drug dose and plasma concentration. There was no significant difference in dose-related serum levels of either drug between the groups.

The hypothesis that patients with tardive dyskinesia develop the syndrome because they do not metabolise neuroleptics as efficiently as those without the syndrome was not supported by the data.

Type
Research Article
Copyright
Copyright © 1983 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Braithwaite, R. A., Dawling, S. & Montgomery, S. A. (1982) Prediction of steady state plasma concentrations and individual dosage regimens of tricyclic antidepressants from a single test dose. Therapeutic Drug Monitoring, 4, 2731.Google Scholar
Brandon, S., McClelland, H. & Protheroe, C. (1971) A study of facial dyskinesia in a mental hospital population. British Journal of Psychiatry, 118, 171–84.Google Scholar
Curry, S. H., Whelpston, R., de Schepper, P. J. et al (1979) Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. British Journal of Clinical Pharmacology, 7, 325–31.Google Scholar
Famuyiwa, O., Eccleston, D., Donaldson, A. A. & Garside, R. F. (1979) Tardive dyskinesia and dementia. British Journal of Psychiatry, 26, 5763.Google Scholar
Feighner, J. P., Robins, E., Guze, S. B., Woodruff, R. A., Winokur, G. & Munoz, R. (1972) Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry, 26, 5763.Google Scholar
Jeste, D. V., Rosenbalalt, J. E., Wagner, R. L. & Wyalt, R. J. (1979) High serum neuroleptic levels in tardive dyskinesia? The New England Journal of Medicine, 301, 1184.Google Scholar
Jørgensen, A. (1980) Pharmacokinetic studies in volunteers of intravenous and oral cis(z)-flupenthixol and intramuscular cis(z)-flupenthixol decanoate in viscoleo. European Journal of Clinical Pharmacology, 18, 355–60.CrossRefGoogle Scholar
Kane, J. M. & Smith, J. M. (1982) Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Archives of General Psychiatry, 39, 473–81.Google Scholar
Lancet (1979) Tardive dyskinesia (leading article). Lancet, 2, 447.Google Scholar
Rowell, F. J., Hui, S. M. & Paxton, J. W. (1979) Evaluation of a radioimmunoassay for phenothiazines and thioxanthines using an iodinated tracer. Journal of Immunological Methods, 31, 159–66.Google Scholar
Rowell, F. J., Hui, S. M., Fairbairn, A. F. & Eccleston, D. (1980) The effect of age and thioridazine on the in vitro binding of fluphenazine to normal human serum. British Journal of Clinical Pharmacology, 9, 432–34.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.